计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Morinidazole is an orally active and 5-nitroimidazole antimicrobial agent that undergoes extensive metabolism in humans via N + -glucuronidation and sulfation. Morinidazole can be used for bacterial infections research including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria
In Vitro
Morinidazole can be metabolized to N + -glucuronide of S-morinidazole [M8-1] and N + -glucuronide of R-morinidazole [M8-2] via N + -glucuronidation, and sulfate conjugate of morinidazole [M7] via sulfation. M7 is a substrate for organic anion transporter 1 (OAT1) and OAT3 (K m =28.6 and 54.0 μM, respectively), M8-1 and M8-2 are the substrates for OAT3. Morinidazole shows activity against Trichomonas vaginalis and Entamoeba histolytica in vitro, with MIC values of 2 μg/mL and 3 μg/mL, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Morinidazole (20 mg/kg or 25 mg/kg; p.o.; single dose) inhibits Trichomonas vaginalis and Entamoeba histolytica in vivo in rats with EC 50 s of 20 mg/kg and 25 mg/kg, respectively. Morinidazole (50 mg/kg; i.v.; 0.25, 0.75, 1.5 h) shows a different concentration in tissues after intravenous injection, with a higher concentration in liver, kidney, plasma than lung, heart, and spleen in mice. Pharmacokinetic parameters of Morinidazole in control and 5/6 nephrectomized (Nx) ratsGroup C max (μg/mL) T max (h) T 1/2 (h) AUC 0-t (μg·h/mL) AUC 0-∞ (μg·h/mL) CL (mL/h/kg) V ss (mL/kg) MRT (h) Control rats 48.2 0.08 1.16 87.2 87.3 582 805 1.39 5/6 Nx rats 53.2 0.08 1.32 91.2 91.3 552 891 1.62 Intravenous injection; 50 mg/kg Morinidazole; Blood samples were collected from retro-orbital venous plexus before the dose (0 hours), at 5, 15, and 30 minutes, and at 1, 2, 4, 6, 8, and 12 hours after the dose. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Renal failure model in SD rats (180-220 g)Dosage: 50 mg/kg Administration: Intravenous injection; sacrificed rats at 0.25, 0.75, and 1.50 hours after dose administration Result: Increased plasma exposures slightly compared with control.
Form:Solid
IC50& Target:organic anion transporter
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 唑类 |
| 亚类(Subclass) | 咪唑类 |
| 中间层级节点(Intermediate Tree Nodes) | 取代咪唑 |
| 直接上位类(Direct Parent) | 硝基咪唑类 |
| 其他上位类(Alternative Parents) | 1,2,5-三取代咪唑 硝基芳香化合物 吗啉 N-取代咪唑 杂芳族化合物 仲醇 三烷基胺 1,2-氨基醇 有机氧氮化合物 氧环化合物 炔丙基型1,3-偶极有机化合物 二烷基醚 氮杂环化合物 有机盐 有机氧化物 碳氢化合物衍生物 有机两性离子 |
| 分子骨架(Molecular Framework) | 芳香族杂单环化合物 |
| 取代基(Substituents) | 1,2-氨基醇 - 1,2,5-三取代咪唑 - 羟基苯甲酸酯 - 烯丙基硫醚 - 氨基酸 - 芳香族杂单环化合物 - 氮杂环 - C-硝基化合物 - 二烷基醚 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - Morpholine - N-取代咪唑 - 硝基芳烃化合物 - 硝基咪唑 - 有机1,3-双极性化合物 - 有机硝基化合物 - 有机硝基化合物 - 有机氧化物 - 有机氧氮化合物 - 有机氧化合物 - 有机盐 - 有机双性离子 - 有机氮化合物 - 有机氧化合物 - 氧杂环 - 氧杂吡嗪烷 - 丙炔型1,3-双极性有机化合物 - 醛基 - 三元脂肪胺 - 三芳基胺 - 三取代咪唑 |
| 描述(Description) | 该化合物属于硝基咪唑类有机化合物。这类化合物含有带硝基的咪唑环。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|